By proposing Cx43 as a new druggable target, this study can open new avenues for the treatment of diseases associated with loss of lysosomal activity and membrane repair capacity, namely in lysosomal storage, infection, neurodegeneration and aging-related disorders, where exocytosis enhancement could ameliorate the pathophysiological conditions. Here, GJA1 is linked to infection.